business intelligence report - (RNAI), a developer of a new clas

This business intelligence report details the significant acquisition of Sirna Therapeutics, Inc. (RNAI) by pharmaceutical giant Merck & Co., Inc. (MRK). The deal, valued at an estimated $1.1 billion in cash, aimed to integrate Sirna's pioneering RNA interference (RNAi) technology into Merck's drug development pipeline, signaling a strategic move into a promising new class of medicines.

What Were the Terms of the Merck-Sirna Acquisition?

The acquisition, announced in late 2006, stipulated that Merck would purchase 100% of Sirna's equity at a price of $13 per share in cash. This made Sirna a wholly owned subsidiary of Merck. Sirna's